|Articles|December 15, 2013
Creating Better Medicines through Better Conjugation (PDF)
Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships.
Advertisement
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
New Lymphoma Indication for CAR T-Cell Therapy Shapes Pipeline
2
Emerging siRNA Platform Offers New Metabolic Disorder Therapies
3
Biocapacitance as a PAT Tool: Real-Time Biomass Monitoring for Upstream Bioprocessing
4
Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies
5
